What is the name of India's first indigenous CRISPR-based gene therapy for Sickle Cell Disease, launched in November 2025?
BIRSA 101
India's first indigenous CRISPR-based gene therapy for Sickle Cell Disease is named BIRSA 101, launched in November 2025.
CRISPR gene-editing technology allows precise correction of the faulty gene responsible for Sickle Cell Disease, a hereditary blood disorder that distorts red blood cells into a sickle shape.
Developing this therapy indigenously marks a major step for India in advanced medical biotechnology and in tackling a disease common among tribal populations.
Hence, the therapy is named BIRSA 101.
Similar Questions
Under an MoU signed on 2 September 2025 between the Department of Ex-Servicemen Welfare and Patanjali Yoggram, nearly six million veterans and their dependents will receive free access to which type of treatment?
In April 2025, BRIC-InStem in Bengaluru collaborated with which medical institution to successfully conduct India’s first gene therapy trial for Haemophilia?
Which international health day was celebrated on November 14, 2025?
What was the theme for World Leprosy Day 2025?
- As per World Health Organization, keeping salt intake to less than ______ helps to prevent hypertension, and reduces the risk of heart disease and stroke in the adult population.
Important Questions from Health
- As per the NFHS-5 (2019-21), what is the approximate percentage of households in India with access to improved sanitation facilities?
Who led the team that explored innovative approaches to combat Alzheimer’s disease at the Bose Institute?
Which parasitic disease has Niger officially eliminated as a public health threat?
Which country has initiated the first-ever clinical trial for a vaccine targeting the Sudan species of the Ebola virus?
Consider the following statements:
Statement-I- Biolumpivaxin vaccine is expected to provide long-lasting immunity against all strains of the Lumpy Skin Disease virus.
Statement-II- Vaccines typically stimulate the immune system to produce antibodies that can neutralize the specific pathogen they are designed to target
Which one of the following is correct in respect to the above statements?
